Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Combinatorial Chemistry & High Throughput Screening
  4. Fast Track Articles
  5. Fast Track Article
image of Dulaglutide Alleviates Alzheimer's Disease by Regulating Microglial Polarization and Neurogenic Activity

Abstract

Backgrounds

Increasing research has proved that microglial activation, polarization, and inflammatory response in the brain affect the pathology of Alzheimer's disease. Hence, employing reagents targeted to microglial functions to optimize the brain microenvironment may become a promising therapeutic method for Alzheimer's disease.

Methods

The phagocytosis and clearance of Aβ1-42 were detected using western blot and immunofluorescence assay. The cell viability was determined 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) or cell counting kit-8 (CCK-8) assay. The load of pro-inflammation, in addition to anti-inflammation factors, was measured through an enzyme-linked immunosorbent (ELISA) assay. Flow cytometry was employed to estimate the apoptotic cells. The protein level related to microglial polarization and neuronal injury was detected western blot. The length of the neuronal synapse was investigated using an immunofluorescence assay.

Results

Dulaglutide significantly promoted microglia to phagocytose and removed the Aβ plague. Additionally, dulaglutide treatment inhibited the production of pro-inflammatory factors, including tumor necrosis factor (TNF)-α, interleukin -1β, and IL-6, whereas it increased the load of anti-inflammatory molecules, such as IL-10 affected by Aβ1-42 exposure. Further investigation verified that Aβ1-42 down-regulated YM1/2 positive M2 microglial polarization phenotype but up-regulated cyclooxygenase-2 (Cox2) positive M1 microglia. However, treating with dulaglutide effectively counteracted these effects. Moreover, dulaglutide dramatically recovered primary cortical neuron cell viability and inhibited cell apoptosis influenced by Aβ1-42. Furthermore, the dulaglutide also reversed neuronal synapse injury after exposure to Aβ1-42.

Conclusion

Altogether, this investigation verified that dulaglutide improved Aβ-induced inflammation and neuronal injury by mediating the activation and polarization of microglia, thereby alleviating Alzheimer's disease efficiently.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cchts/10.2174/1386207325666220726163514
2024-11-27
2025-03-01

  • From This Site

    /content/journals/cchts/10.2174/1386207325666220726163514
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Shaw A.R. Perales-Puchalt J. Bright B. Moore T. Robinson M. Hill C.V. Vidoni E.J. Recruitment of older African Americans in Alzheimers disease clinical trials using a community based research approach. medRxiv 2020 Available from: medrxiv.org/content/10.1101/2020.07.16.20155556v2.article-info
    [Google Scholar]
  2. Borson S. Frank L. Bayley P.J. Boustani M. Dean M. Lin P-J. McCarten J.R. Morris J.C. Salmon D.P. Schmitt F.A.J.A. Dementia, improving dementia care: The role of screening and detection of cognitive impairment. Alzheimers Dement. 2013 9 2 151 159
    [Google Scholar]
  3. Krsteska R.J.M. The affective disturbance in people with Alzheimer’ and vascular dementia. Inter. Res. J. 2019 8-1 86 72 74
    [Google Scholar]
  4. Long J.M. Holtzman D.M. Alzheimer disease: An update on pathobiology and treatment strategies. Cell 2019 179 2 312 339 10.1016/j.cell.2019.09.001 31564456
    [Google Scholar]
  5. Sarlus H. Heneka M.T. Microglia in Alzheimer’s disease. J. Clin. Invest. 2017 127 9 3240 3249 10.1172/JCI90606 28862638
    [Google Scholar]
  6. Mir R.H. Sawhney G. Pottoo F.H. Mohi-Ud-Din R. Madishetti S. Jachak S.M. Ahmed Z. Masoodi M.H.J.E.S. Role of environmental pollutants in Alzheimer’s disease: A review. Environ. Sci. Pollut. Res. Int. 2020 27 36 44724 10.1007/s11356‑020‑09964‑x
    [Google Scholar]
  7. Mir R.H. Shah A.J. Mohi-Ud-Din R. Potoo F.H. Dar M. Jachak S.M. Masoodi M.H.J.C.m.c. Natural anti-inflammatory compounds as drug candidates in Alzheimer’s disease. Curr. Med. Chem. 2021 28 23 4799 4825 10.2174/0929867327666200730213215
    [Google Scholar]
  8. Hardy J. The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal. J. Neurochem. 2009 110 4 1129 1134 10.1111/j.1471‑4159.2009.06181.x 19457065
    [Google Scholar]
  9. Mohi-Ud-Din R. Mir R.H. Wani T.U. Shah A.J. Banday N. Pottoo F.H.J.C.C. Screening H.T. Berberine in the treatment of neurodegenerative diseases and nanotechnology enabled targeted delivery. Comb. Chem. High Throughput Screen. 2022 25 4 616 633
    [Google Scholar]
  10. Mohi-Ud-Din R. Mir R.H. Wani T.U. Shah A.J. Mohi-Ud-Din I. Dar M.A. Pottoo F.H.J.C. Novel drug delivery system for curcumin: Implementation to improve therapeutic efficacy against neurological disorders. Comb. Chem. High Throughput Screen. 2021 25 4 607 615
    [Google Scholar]
  11. Su Y. Chang P.T. Acidic pH promotes the formation of toxic fibrils from beta-amyloid peptide. Brain Res. 2001 893 1-2 287 291 10.1016/S0006‑8993(00)03322‑9 11223020
    [Google Scholar]
  12. Hu X. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc. Natl. Acad. Sci. USA 2009 106 20324-20329
    [Google Scholar]
  13. Mosser C.A. Baptista S. Arnoux I. Audinat E. Microglia in CNS development: Shaping the brain for the future. Prog. Neurobiol. 2017 149-150 1 20 10.1016/j.pneurobio.2017.01.002 28143732
    [Google Scholar]
  14. Orihuela R. McPherson C.A. Harry G.J. Microglial M1/M2 polarization and metabolic states. Br. J. Pharmacol. 2016 173 4 649 665 10.1111/bph.13139 25800044
    [Google Scholar]
  15. Hickman S.E. Allison E.K. El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer’s disease mice. J. Neurosci. 2008 28 33 8354 8360 10.1523/JNEUROSCI.0616‑08.2008 18701698
    [Google Scholar]
  16. Daria A. Colombo A. Llovera G. Hampel H. Willem M. Liesz A. Haass C. Tahirovic S. Young microglia restore amyloid plaque clearance of aged microglia. EMBO J. 2017 36 5 583 603 10.15252/embj.201694591 28007893
    [Google Scholar]
  17. Hellwig S. Masuch A. Nestel S. Katzmarski N. Meyer-Luehmann M. Biber K. Forebrain microglia from wild-type but not adult 5xFAD mice prevent amyloid-β plaque formation in organotypic hippocampal slice cultures. Sci. Rep. 2015 5 1 14624 10.1038/srep14624 26416689
    [Google Scholar]
  18. Spangenberg E.E. Lee R.J. Najafi A.R. Rice R.A. Elmore M.R. Blurton-Jones M. West B.L. Green K.N. Eliminating microglia in Alzheimer’s mice prevents neuronal loss without modulating amyloid-β pathology. Brain 2016 139 Pt 4 1265 1281 10.1093/brain/aww016 26921617
    [Google Scholar]
  19. Saijo K. Glass C.K. Microglial cell origin and phenotypes in health and disease. Nat. Rev. Immunol. 2011 11 11 775 787 10.1038/nri3086 22025055
    [Google Scholar]
  20. Mantovani A. Biswas S.K. Galdiero M.R. Sica A. Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J. Pathol. 2013 229 2 176 185 10.1002/path.4133 23096265
    [Google Scholar]
  21. Hu X. Leak R.K. Shi Y. Suenaga J. Gao Y. Zheng P. Chen J. Microglial and macrophage polarization-New prospects for brain repair. Nat. Rev. Neurol. 2015 11 1 56 64 10.1038/nrneurol.2014.207 25385337
    [Google Scholar]
  22. Miron V.E. Boyd A. Zhao J.W. Yuen T.J. Ruckh J.M. Shadrach J.L. van Wijngaarden P. Wagers A.J. Williams A. Franklin R.J.M. Ffrench-Constant C. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat. Neurosci. 2013 16 9 1211 1218 10.1038/nn.3469 23872599
    [Google Scholar]
  23. Miguel-Álvarez M. Santos-Lozano A. Sanchis-Gomar F. Fiuza-Luces C. Pareja-Galeano H. Garatachea N. Lucia A. Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer’s disease: A systematic review and meta-analysis of treatment effect. Drugs Aging 2015 32 2 139 147 10.1007/s40266‑015‑0239‑z 25644018
    [Google Scholar]
  24. Hölscher C. Central effects of GLP-1: New opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 2014 221 1 T31 T41 10.1530/JOE‑13‑0221 23999914
    [Google Scholar]
  25. Eakin K. Li Y. Chiang Y.H. Hoffer B.J. Rosenheim H. Greig N.H. Miller J.P. Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. PLoS One 2013 8 12 e82016 10.1371/journal.pone.0082016 24312624
    [Google Scholar]
  26. Darsalia V. Mansouri S. Ortsäter H. Olverling A. Nozadze N. Kappe C. Iverfeldt K. Tracy L.M. Grankvist N. Sjöholm Å. Patrone C. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin. Sci. (Lond.) 2012 122 10 473 483 10.1042/CS20110374 22150224
    [Google Scholar]
  27. Chen S. Liu A.R. An F.M. Yao W.B. Gao X.D. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer’s disease by exendin-4. Age (Dordr.) 2012 34 5 1211 1224 10.1007/s11357‑011‑9303‑8 21901364
    [Google Scholar]
  28. Kim S. Moon M. Park S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson’s disease. J. Endocrinol. 2009 202 3 431 439 10.1677/JOE‑09‑0132 19570816
    [Google Scholar]
  29. Li Y. Rosenblit P.D. Glucagon-like peptide-1 receptor agonists and cardiovascular risk reduction in Type 2 Diabetes mellitus: Is it a class effect? Curr. Cardiol. Rep. 2018 20 11 113 10.1007/s11886‑018‑1051‑2 30259238
    [Google Scholar]
  30. Zhou M. Chen S. Peng P. Gu Z. Yu J. Zhao G. Deng Y. Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3β. Biochem. Biophys. Res. Commun. 2019 511 1 154 160 10.1016/j.bbrc.2019.01.103 30773255
    [Google Scholar]
  31. Kim S.M. Mun B.R. Lee S.J. Joh Y. Lee H.Y. Ji K.Y. Choi H.R. Lee E.H. Kim E.M. Jang J.H. Song H.W. Mook-Jung I. Choi W.S. Kang H.S. TREM2 promotes Aβ phagocytosis by upregulating C/EBPα-dependent CD36 expression in microglia. Sci. Rep. 2017 7 1 11118 10.1038/s41598‑017‑11634‑x 28894284
    [Google Scholar]
  32. Zhao Y. Wu X. Li X. Jiang L.L. Gui X. Liu Y. Sun Y. Zhu B. Piña-Crespo J.C. Zhang M. Zhang N. Chen X. Bu G. An Z. Huang T.Y. Xu H. TREM2 is a receptor for β-amyloid that mediates microglial function. Neuron 2018 97 5 1023 1031.e7 10.1016/j.neuron.2018.01.031 29518356
    [Google Scholar]
  33. Lee J. Kim D.E. Griffin P. Sheehan P.W. Kim D.H. Musiek E.S. Yoon S.Y. Inhibition of REV-ERBs stimulates microglial amyloid-beta clearance and reduces amyloid plaque deposition in the 5XFAD mouse model of Alzheimer’s disease. Aging Cell 2020 19 2 e13078 10.1111/acel.13078 31800167
    [Google Scholar]
  34. Zheng X. Gan H. Li L. Hu X. Fang Y. Chu L. Astragaloside IV inhibits inflammation after cerebral ischemia in rats through promoting microglia/macrophage M2 polarization. Zhejiang Da Xue Xue Bao Yi Xue Ban 2020 49 6 679 686 33448170
    [Google Scholar]
  35. Latta-Mahieu M. Elmer B. Bretteville A. Wang Y. Lopez-Grancha M. Goniot P. Moindrot N. Ferrari P. Blanc V. Schussler N. Brault E. Roudières V. Blanchard V. Yang Z.Y. Barneoud P. Bertrand P. Roucourt B. Carmans S. Bottelbergs A. Mertens L. Wintmolders C. Larsen P. Hersley C. McGathey T. Racke M.M. Liu L. Lu J. O’Neill M.J. Riddell D.R. Ebneth A. Nabel G.J. Pradier L. Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models. Glia 2018 66 3 492 504 10.1002/glia.23260 29134678
    [Google Scholar]
  36. Perry V.H. Holmes C. Microglial priming in neurodegenerative disease. Nat. Rev. Neurol. 2014 10 4 217 224 10.1038/nrneurol.2014.38 24638131
    [Google Scholar]
  37. Perry V.H. Nicoll J.A. Holmes C. Microglia in neurodegenerative disease. Nat. Rev. Neurol. 2010 6 4 193 201 10.1038/nrneurol.2010.17 20234358
    [Google Scholar]
  38. Fiala M. Restrepo L. Pellegrini M. Immunotherapy of mild cognitive impairment by ω-3 supplementation: Why are amyloid-β antibodies and ω-3 not working in clinical trials? J. Alzheimers Dis. 2018 62 3 1013 1022 10.3233/JAD‑170579 29103035
    [Google Scholar]
  39. Maezawa I. Nguyen H.M. Di Lucente J. Jenkins D.P. Singh V. Hilt S. Kim K. Rangaraju S. Levey A.I. Wulff H. Jin L.W. Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer’s disease: Preclinical proof of concept. Brain 2018 141 2 596 612 10.1093/brain/awx346 29272333
    [Google Scholar]
  40. Tang Y. Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol. Neurobiol. 2016 53 2 1181 1194 10.1007/s12035‑014‑9070‑5 25598354
    [Google Scholar]
  41. Arcuri C. Mecca C. Bianchi R. Giambanco I. Donato R. The pathophysiological role of microglia in dynamic surveillance, phagocytosis and structural remodeling of the developing CNS. Front. Mol. Neurosci. 2017 10 191 10.3389/fnmol.2017.00191 28674485
    [Google Scholar]
  42. Aryanpour R. Pasbakhsh P. Zibara K. Namjoo Z. Beigi Boroujeni F. Shahbeigi S. Kashani I.R. Beyer C. Zendehdel A. Progesterone therapy induces an M1 to M2 switch in microglia phenotype and suppresses NLRP3 inflammasome in a cuprizone-induced demyelination mouse model. Int. Immunopharmacol. 2017 51 131 139 10.1016/j.intimp.2017.08.007 28830026
    [Google Scholar]
  43. O’Halloran S. O’Leary A. Kuijper T. Downer E.J. MyD88 acts as an adaptor protein for inflammatory signalling induced by amyloid-β in macrophages. Immunol. Lett. 2014 162 1 1 Pt A 109 118 10.1016/j.imlet.2014.08.001 25124962
    [Google Scholar]
  44. Jiang D. Gong F. Ge X. Lv C. Huang C. Feng S. Zhou Z. Rong Y. Wang J. Ji C. Chen J. Zhao W. Fan J. Liu W. Cai W. Neuron-derived exosomes-transmitted miR-124-3p protect traumatically injured spinal cord by suppressing the activation of neurotoxic microglia and astrocytes. J. Nanobiotechnology 2020 18 1 105 10.1186/s12951‑020‑00665‑8 32711535
    [Google Scholar]
/content/journals/cchts/10.2174/1386207325666220726163514
Loading
Dulaglutide Alleviates Alzheimer's Disease by Regulating Microglial Polarization and Neurogenic Activity
Bentham Science Publishers ; https://doi.org/10.2174/1386207325666220726163514
/content/journals/cchts/10.2174/1386207325666220726163514
/content/journals/cchts/10.2174/1386207325666220726163514
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: Dulaglutide ; neurogenic activity ; demantia ; microglial polarization ; Alzheimer's disease

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test